Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

June 23, 2026

IMUNON to Present at the Life Sciences Investor Forum on June 25th

June 22, 2026

IMUNON Announces Up to $10 Million Cash Financing

June 4, 2026

Financial Events

Presentation at the Zacks SCR Life Sciences Virtual Investor Forum

June 25, 2026

Imunon First Quarter 2026 Financial Results

May 12, 2026 at 11:00 AM EDT